Surface Oncology Analyst Ratings
Surface Oncology Analyst Ratings
While ratings are subjective and will change, the latest Surface Oncology (SURF) rating was a maintained with a price target of $8.50 to $6.00. The current price Surface Oncology (SURF) is trading at is $1.29, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2022 | 365.12% | HC Wainwright & Co. | $8.5 → $6 | Maintains | Buy |
| 08/08/2022 | 558.91% | HC Wainwright & Co. | $10 → $8.5 | Maintains | Buy |
| 05/18/2021 | 1217.83% | BTIG | → $17 | Initiates Coverage On | → Buy |
| 09/04/2020 | 752.71% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 08/28/2020 | 830.23% | Wedbush | → $12 | Initiates Coverage On | → Outperform |
| 09/19/2018 | 1682.95% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 05/14/2018 | 1217.83% | Goldman Sachs | → $17 | Initiates Coverage On | → Neutral |
| 05/14/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 05/14/2018 | 1915.5% | Evercore ISI Group | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/03/2022 | 365.12% | HC Wainwright & Co. | 8.5 美元 → 6 美元 | 维护 | 买 |
| 08/08/2022 | 558.91% | HC Wainwright & Co. | 10 美元 → 8.5 美元 | 维护 | 买 |
| 05/18/2021 | 1217.83% | BTIG | → 17 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 4 月 9 日 | 752.71% | HC Wainwright & Co. | → 11 美元 | 启动覆盖范围开启 | → 购买 |
| 08/28/2020 | 830.23% | Wedbush | → 12 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 09/19/2018 | 1682.95% | 贝尔德 | → 23 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 05/14/2018 | 1217.83% | 高盛 | → 17 美元 | 启动覆盖范围开启 | → 中立 |
| 05/14/2018 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 05/14/2018 | 1915.5% | Evercore ISI 集团 | → 26 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
Surface Oncology Questions & Answers
表面肿瘤学问题与解答
The latest price target for Surface Oncology (NASDAQ: SURF) was reported by HC Wainwright & Co. on November 3, 2022. The analyst firm set a price target for $6.00 expecting SURF to rise to within 12 months (a possible 365.12% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年11月3日公布了表面肿瘤学（纳斯达克股票代码：SURF）的最新目标股价。该分析公司将目标股价定为6.00美元，预计SURF将在12个月内升至12个月内（可能上涨365.12％）。去年有2家分析公司公布了评级。
The latest analyst rating for Surface Oncology (NASDAQ: SURF) was provided by HC Wainwright & Co., and Surface Oncology maintained their buy rating.
表面肿瘤学（纳斯达克股票代码：SURF）的最新分析师评级由HC Wainwright & Co. 提供，表面肿瘤学维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surface Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surface Oncology was filed on November 3, 2022 so you should expect the next rating to be made available sometime around November 3, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Surface Oncology的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。表面肿瘤学的最新评级是在2022年11月3日发布的，因此您应该预计下一个评级将在2023年11月3日左右公布。
While ratings are subjective and will change, the latest Surface Oncology (SURF) rating was a maintained with a price target of $8.50 to $6.00. The current price Surface Oncology (SURF) is trading at is $1.29, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的表面肿瘤学（SURF）评级保持不变，目标股价为8.50美元至6.00美元。表面肿瘤学（SURF）目前的交易价格为1.29美元，超出了分析师的预期区间。